Atala Financial Inc Purchases New Position in Amgen Inc. (NASDAQ:AMGN)

Atala Financial Inc purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 132 shares of the medical research company’s stock, valued at approximately $34,000.

Other institutional investors have also bought and sold shares of the company. Centricity Wealth Management LLC acquired a new stake in Amgen in the 4th quarter valued at $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the third quarter worth $29,000. Synergy Investment Management LLC acquired a new position in Amgen in the fourth quarter worth $34,000. Heck Capital Advisors LLC acquired a new position in Amgen in the fourth quarter worth $36,000. Finally, PrairieView Partners LLC boosted its stake in Amgen by 118.3% in the fourth quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock worth $46,000 after purchasing an additional 97 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.3 %

NASDAQ AMGN opened at $313.71 on Friday. The stock has a 50-day simple moving average of $291.82 and a 200 day simple moving average of $299.52. The company has a market capitalization of $168.53 billion, a PE ratio of 41.55, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.03%. Amgen’s payout ratio is 126.09%.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Redburn Partners reduced their price objective on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Citigroup reissued a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. UBS Group reissued a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Finally, Johnson Rice set a $294.00 target price on Amgen in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $314.04.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.